Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
CTI BioPharma Corp.

CTI BioPharma Corp. (CTIC) Stock Overview

Explore CTI BioPharma Corp.’s financial performance, market position, analyst ratings, and future outlook.

CTIC●NASDAQ
HealthcareBiotechnology
$9.10
$0.005(0.06%)
U.S. Market opens in 38h 31m

CTI BioPharma Corp. (CTIC)

Meyka AI Score

Z

Key Financials

Market Cap1.2B
P/E Ratio-11.51
EPS (TTM)$-0.54
ROE13.18%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$14.11

CTIC Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of CTI BioPharma Corp. (NASDAQ: CTIC) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, CTI BioPharma Corp.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of CTIC on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $14.11 for the NASDAQ listing.

Key metrics behind CTI BioPharma Corp.'s NASDAQ-traded stock include a P/E ratio of -11.51 and a market capitalization of 1.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CTIC on the NASDAQ.

Price Performance (NASDAQ: CTIC)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
0.06%
3-Month Change
71.60%
6-Month Change
53.63%
Year-to-Date (YTD) Change
55.20%
1-Year Change
50.33%
3-Year Change
447.89%
5-Year Change
300.66%
All-Time (Max) Change
-99.99%

Contact Information

https://www.ctibiopharma.com
206 282 7100
3101 Western Avenue, Seattle, WA, 98121

Company Facts

1,270 Employees
IPO DateMar 21, 1997
CountryUS

Frequently Asked Questions